Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Advances in therapeutic cancer vaccines: Harnessing immune adjuvants for enhanced efficacy and future perspectives. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1038/nm.3409
10.1038/nm.3409 · External reference
mRNA vaccine for cancer immunotherapy
10.1186/s12943-021-01335-5 · 2021 · External reference
10.1146/annurev.micro.112408.134019
10.1146/annurev.micro.112408.134019 · External reference
10.1023/a:1008344502623
10.1023/a:1008344502623 · External reference
Precision medicine in head and neck cancer
10.1016/j.drup.2018.09.001 · 2018 · External reference
10.1038/s41568-021-00346-0
10.1038/s41568-021-00346-0 · External reference
10.1038/s41551-022-01000-2
10.1038/s41551-022-01000-2 · External reference
10.3390/cells9092061
10.3390/cells9092061 · External reference
mRNA therapeutics in cancer immunotherapy
10.1186/s12943-021-01348-0 · 2021 · External reference
10.1016/j.coi.2020.01.006
10.1016/j.coi.2020.01.006 · External reference
In situ vaccination: Harvesting low hanging fruit on the cancer immunotherapy tree
2019 · External reference
In situ vaccination using unique TLR9 ligand K3-SPG induces long-lasting systemic immune response and synergizes with systemic and local immunotherapy
10.1038/s41598-022-05702-0 · 2022 · External reference
The vaccine-site microenvironment: impacts of antigen, adjuvant, and same-site vaccination on antigen presentation and immune signaling
10.1136/jitc-2021-003533 · 2022 · External reference
10.1038/nm933
10.1038/nm933 · External reference
10.1111/jcmm.14356
10.1111/jcmm.14356 · External reference
10.1039/d1cc04604g
10.1039/d1cc04604g · External reference
High-Z-sensitized radiotherapy synergizes with the intervention of the pentose phosphate pathway for in situ tumor vaccination
10.1002/adma.202109726 · 2022 · External reference
10.1038/nature23003
10.1038/nature23003 · External reference
10.1038/s41573-021-00387-y
10.1038/s41573-021-00387-y · External reference
10.1038/nri.2017.131
10.1038/nri.2017.131 · External reference
10.1038/s41571-020-00460-2
10.1038/s41571-020-00460-2 · External reference
10.1093/infdis/jit236
10.1093/infdis/jit236 · External reference
Third-generation vaccines: features of nucleic acid vaccines and strategies to improve their efficiency
10.3390/genes13122287 · 2022 · External reference
10.1038/s41551-018-0250-x
10.1038/s41551-018-0250-x · External reference
CpG adjuvant in allergen-specific immunotherapy: finding the sweet spot for the induction of immune tolerance
10.3389/fimmu.2021.590054 · 2021 · External reference
TLR-9 agonist immunostimulatory sequence adjuvants linked to cancer antigens
10.1007/978-1-4939-0345-0_27 · 2014 · External reference
Autologous tumor lysate-loaded dendritic cell vaccination (DCVax-L) in glioblastoma: Breakthrough or fata morgana?
10.1093/neuonc/noac281 · 2023 · External reference
10.1039/d1tb01408k
10.1039/d1tb01408k · External reference
Clinical advances and ongoing trials on mRNA vaccines for cancer treatment
10.1016/s1470-2045(22)00372-2 · 2022 · External reference
COVID-19 vaccine success enables a bolder vision for mRNA cancer vaccines, says BioNTech CEO
10.1038/d41573-021-00110-x · 2021 · External reference
Trial watch: TLR3 agonists in cancer therapy
2020 · External reference
10.1002/jlb.5mir0420-055r
10.1002/jlb.5mir0420-055r · External reference
Comb-structured mRNA vaccine tethered with short double-stranded RNA adjuvants maximizes cellular immunity for cancer treatment
10.1073/pnas.2214320120 · 2023 · External reference
Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage IV renal cell cancer in Japan: clinical and immunological findings
10.1016/j.ymthe.2004.07.001 · 2004 · External reference
Engineering dendritic cell vaccines to improve cancer immunotherapy
10.1038/s41467-019-13368-y · 2019 · External reference
10.1172/jci31205
10.1172/jci31205 · External reference
Sipuleucel-T immunotherapy for castration-resistant prostate cancer
10.1056/nejmoa1001294 · 2010 · External reference
Sipuleucel-T
10.1038/nrd3220 · 2010 · External reference
10.1016/j.bioactmat.2020.09.002
10.1016/j.bioactmat.2020.09.002 · External reference
Type 1 conventional dendritic cells are systemically dysregulated early in pancreatic carcinogenesis
2020 · External reference
10.1038/nrc3258
10.1038/nrc3258 · External reference
10.1038/s41568-022-00462-5
10.1038/s41568-022-00462-5 · External reference
10.3390/pharmaceutics14081572
10.3390/pharmaceutics14081572 · External reference
10.1007/s00262-022-03144-1
10.1007/s00262-022-03144-1 · External reference
Mechanisms of action of adjuvants
10.3389/fimmu.2013.00114 · 2013 · External reference
10.2165/11591760-000000000-00000
10.2165/11591760-000000000-00000 · External reference
Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases
10.1586/14760584.2016.1124763 · 2016 · External reference
An aluminum adjuvant-integrated nano-MOF as antigen delivery system to induce strong humoral and cellular immune responses
10.1016/j.jconrel.2019.02.035 · 2019 · External reference
Adjuvants for peptide-based cancer vaccines
10.1186/s40425-016-0160-y · 2016 · External reference
Incomplete Freund's adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment
10.1136/jitc-2020-000544 · 2020 · External reference
Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine
10.1200/jco.2010.33.8053 · 2011 · External reference
Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial
10.1158/1078-0432.ccr-09-1544 · 2009 · External reference
Supramolecular assembled programmable nanomedicine as in situ cancer vaccine for cancer immunotherapy
10.1002/adma.202007293 · 2021 · External reference
10.1016/j.actbio.2023.02.034
10.1016/j.actbio.2023.02.034 · External reference
10.1016/j.addr.2007.05.017
10.1016/j.addr.2007.05.017 · External reference
10.1039/d2cc05016a
10.1039/d2cc05016a · External reference
10.1039/c4nr07677j
10.1039/c4nr07677j · External reference
10.1007/s00262-021-02946-z
10.1007/s00262-021-02946-z · External reference
Supramolecular theranostic nanomedicine for in situ self-boosting cancer photochemotherapy
10.1021/acs.biomac.2c01469 · 2023 · External reference
Intratumoral therapies and in-situ vaccination for melanoma
10.1080/21645515.2021.1890512 · 2022 · External reference
Nanoparticle interactions with immune cells dominate tumor retention and induce T cell-mediated tumor suppression in models of breast cancer
10.1126/sciadv.aay1601 · 2020 · External reference
Mutations in IFN-γ signaling genes sensitize tumors to immune checkpoint blockade
10.1016/j.ccell.2023.02.013 · 2023 · External reference
Cytokines as natural adjuvants for vaccines: where are we now?
10.1016/s1471-4906(02)02276-7 · 2002 · External reference
Cytokines as a link between innate and adaptive antitumor immunity
10.1016/s1471-4906(02)02195-6 · 2002 · External reference
10.1158/2159-8290.cd-nb2021-0341
10.1158/2159-8290.cd-nb2021-0341 · External reference
NK cells propagate T cell immunity following in situ tumor vaccination
2023 · External reference
10.1016/j.immuni.2018.09.024
10.1016/j.immuni.2018.09.024 · External reference
GM-CSF elicits antibodies to tumor-associated proteins when used as a prostate cancer vaccine adjuvant
10.1007/s00262-022-03150-3 · 2022 · External reference
10.1158/0008-5472.can-21-1382
10.1158/0008-5472.can-21-1382 · External reference
10.1038/s41591-019-0410-x
10.1038/s41591-019-0410-x · External reference
10.1158/0008-5472.can-18-1429
10.1158/0008-5472.can-18-1429 · External reference
Short-course neoadjuvant in situ vaccination for murine melanoma
10.1136/jitc-2021-003586 · 2022 · External reference
The Immunocytokine FAP-IL-2v enhances anti-neuroblastoma efficacy of the Anti-GD(2) Antibody Dinutuximab Beta
10.3390/cancers14194842 · 2022 · External reference
10.3390/cancers14246091
10.3390/cancers14246091 · External reference
CpG oligonucleotides as immunotherapeutic adjuvants: innovative applications and delivery strategies
10.1016/j.addr.2008.12.003 · 2009 · External reference
10.1007/s00262-022-03315-0
10.1007/s00262-022-03315-0 · External reference
Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer
10.1186/s12943-022-01515-x · 2022 · External reference
10.1038/s41591-021-01323-8
10.1038/s41591-021-01323-8 · External reference
Intratumoral administration of the Toll-like receptor 7/8 agonist 3M-052 enhances interferon-driven tumor immunogenicity and suppresses metastatic spread in preclinical triple-negative breast cancer
10.1002/cti2.1177 · 2020 · External reference
10.1021/acsnano.2c06300
10.1021/acsnano.2c06300 · External reference
10.1158/0008-5472.can-10-1993
10.1158/0008-5472.can-10-1993 · External reference
10.3390/cells9112432
10.3390/cells9112432 · External reference
Delivery of STING agonists for adjuvanting subunit vaccines
10.1016/j.addr.2021.114020 · 2021 · External reference
STING agonist combined to a protein-based cancer vaccine potentiates peripheral and intra-tumoral T cell immunity
10.3389/fimmu.2021.695056 · 2021 · External reference
10.1016/j.immuni.2021.04.019
10.1016/j.immuni.2021.04.019 · External reference
Pim-3 enhances melanoma cell migration and invasion by promoting STAT3 phosphorylation
10.1080/15384047.2017.1414756 · 2018 · External reference
10.1016/j.trecan.2023.02.001
10.1016/j.trecan.2023.02.001 · External reference
10.1111/imr.12550
10.1111/imr.12550 · External reference
Immunogenic cell death-based cancer vaccines
2021 · External reference
10.1039/d1cs00417d
10.1039/d1cs00417d · External reference
10.1021/acs.accounts.2c00360
10.1021/acs.accounts.2c00360 · External reference
Using PAMPs and DAMPs as adjuvants in cancer vaccines
10.1080/21645515.2021.1964316 · 2021 · External reference
10.1038/nri.2017.9
10.1038/nri.2017.9 · External reference
10.1007/s00281-004-0173-3
10.1007/s00281-004-0173-3 · External reference
10.1038/15200
10.1038/15200 · External reference
10.1016/j.canlet.2018.08.028
10.1016/j.canlet.2018.08.028 · External reference
10.1016/j.biomaterials.2016.06.032
10.1016/j.biomaterials.2016.06.032 · External reference
Research progress in inducing immunogenic cell death of tumor cells
2022 · External reference
Pancreatic cancer-targeting exosomes for enhancing immunotherapy and reprogramming tumor microenvironment
10.1016/j.biomaterials.2020.120546 · 2021 · External reference
10.1016/j.cytogfr.2013.01.005
10.1016/j.cytogfr.2013.01.005 · External reference
10.1080/21645515.2019.1665960
10.1080/21645515.2019.1665960 · External reference
JTC801 Induces pH-dependent death specifically in cancer cells and slows growth of tumors in mice
10.1053/j.gastro.2017.12.004 · 2018 · External reference
Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade glioma
2016 · External reference
Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas
10.1172/jci151239 · 2022 · External reference
Complement as an endogenous adjuvant for dendritic cell-mediated induction of retrovirus-specific CTLs
10.1371/journal.ppat.1000891 · 2010 · External reference
10.1038/s41586-020-2537-9
10.1038/s41586-020-2537-9 · External reference
JA: Revisiting IL-2: Biology and therapeutic prospects
10.1126/sciimmunol.aat1482 · 2018 · External reference
10.1016/j.jconrel.2023.02.015
10.1016/j.jconrel.2023.02.015 · External reference
Updated aluminum pharmacokinetics following infant exposures through diet and vaccination
10.1016/j.vaccine.2011.09.124 · 2011 · External reference
10.1016/j.jconrel.2023.08.049
10.1016/j.jconrel.2023.08.049 · External reference
Cancer Vaccines, Adjuvants, and Delivery Systems
10.3389/fimmu.2021.627932 · 2021 · External reference
Novavax COVID-19 Vaccine Booster Authorized
10.1001/jama.2022.20028 · 2022 · External reference
10.1016/j.addr.2013.05.013
10.1016/j.addr.2013.05.013 · External reference
10.1016/j.immuni.2010.10.002
10.1016/j.immuni.2010.10.002 · External reference
Detection of immunogenic cell death and its relevance for cancer therapy
10.1038/s41419-020-03221-2 · 2020 · External reference
Unveiling the Multifaceted Roles of ISG15: From Immunomodulation to Therapeutic Frontiers
10.3390/vaccines12020153 · 2024 · External reference
10.1111/febs.14467
10.1111/febs.14467 · External reference
10.1038/s41577-018-0066-7
10.1038/s41577-018-0066-7 · External reference
10.3390/cancers13020167
10.3390/cancers13020167 · External reference
10.1038/ni.2366
10.1038/ni.2366 · External reference
10.3390/cancers14215270
10.3390/cancers14215270 · External reference
10.1016/j.coi.2011.08.003
10.1016/j.coi.2011.08.003 · External reference
10.1126/science.abb4255
10.1126/science.abb4255 · External reference
10.1016/j.vaccine.2008.06.099
10.1016/j.vaccine.2008.06.099 · External reference
Progress in c-di-GMP inhibitors
2017 · External reference
A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund's adjuvant in melanoma patients
10.1186/s40425-019-0625-x · 2019 · External reference
Chitosan plus compound 48/80: formulation and preliminary evaluation as a hepatitis b vaccine adjuvant
10.3390/pharmaceutics11020072 · 2019 · External reference
10.1038/emboj.2012.2
10.1038/emboj.2012.2 · External reference
Shikonin induces immunogenic cell death in tumor cells and enhances dendritic cell-based cancer vaccine
10.1007/s00262-012-1258-9 · 2012 · External reference
10.1038/cdd.2014.96
10.1038/cdd.2014.96 · External reference
10.1038/nrurol.2018.10
10.1038/nrurol.2018.10 · External reference
Oncolytic virus-mediated reversal of impaired tumor antigen presentation
10.3389/fonc.2014.00077 · 2014 · External reference
CIMAvax-EGF: a new therapeutic vaccine for advanced non-small cell lung cancer patients
10.3389/fimmu.2017.00269 · 2017 · External reference
PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine
10.1158/1078-0432.ccr-10-3126 · 2011 · External reference
BiovaxID®: a customized idiotype vaccine for the treatment of B-cell lymphoma
10.1586/erv.11.132 · 2011 · External reference
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial
10.1016/s1470-2045(13)70510-2 · 2014 · External reference
10.1200/jco.2012.44.3762
10.1200/jco.2012.44.3762 · External reference
mRNA Vaccine Slows Melanoma Recurrence
10.1158/2159-8290.cd-nb2023-0028 · 2023 · External reference
